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1. Introduction 
Gamma-retroviral vectors, commonly designated retroviral vectors, were the first viral 
vector employed in Gene Therapy clinical trials in 1990 and are still one of the most used. 
More recently, the interest in lentiviral vectors, derived from complex retroviruses such as 
the human immunodeficiency virus (HIV), has been growing due to their ability to 
transduce non-dividing cells (Lewis et al. 1992; Naldini et al. 1996), an attribute that 
distinguishes them from other viral vectors, including their simple counterparts, gamma-
retroviral vectors. Retroviral and lentiviral vectors most attractive features as gene transfer 
tools include the capacity for large genetic payload (up to 9 kb), minimal patient immune 
response, high transducing efficiency in vivo and in vitro, and the ability to permanently 
modify the genetic content of the target cell, sustaining a long-term expression of the 
delivered gene (Coroadinha et al. 2010; Schweizer and Merten 2010). 
According to the most recent updates, retroviral and lentiviral vectors represent 23% of all 
the vector types and 33% of the viral vectors used in Gene Therapy clinical trials. Moreover, 
retroviral vectors are currently the blockbuster vectors for the treatment of monogenic and 
infectious diseases and gene marking clinical trials (Edelstein 2010).  
Retroviruses are double stranded RNA enveloped viruses mainly characterized by the 
ability to “reverse-transcribe” their genome from RNA to DNA. Virions measure 100-120 
nm in diameter and contain a dimeric genome of identical positive RNA strands complexed 
with the nucleocapsid (NC) proteins. The genome is enclosed in a proteic capsid (CA) that 
also contains enzymatic proteins, namely the reverse transcriptase (RT), the integrase (IN) 
and proteases (PR), required for viral infection. The matrix proteins (MA) form a layer 
outside the capsid core that interacts with the envelope, a lipid bilayer derived from the host 
cellular membrane, which surrounds the viral core particle (Coffin et al. 1997). Anchored on 
this bilayer, are the viral envelope glycoproteins (Env) responsible for recognizing specific 
receptors on the host cell and initiating the infection process. Envelope proteins are formed 
by two subunits, the transmembrane (TM) that anchors the protein into the lipid membrane 
and the surface (SU) which binds to the cellular receptors (Fig. 1).  
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Fig. 1. Schematic representation of a retrovirus particle structure. 
Based on the genome structure, retroviruses are classified into simple (e.g. MLV, murine 
leukemia virus) or complex retroviruses (e.g. HIV) (Coffin et al. 1997). Both encode four 
genes: gag (group specific antigen), pro (protease), pol (polymerase) and env (envelope) 
(Fig. 2). The gag sequence encodes the three main structural proteins: MA, CA, NC. The 
pro sequence, encodes proteases (PR) responsible for cleaving Gag and Gag-Pol during 
particles assembly, budding and maturation. The pol sequence encodes the enzymes RT 
and IN, the former catalyzing the reverse transcription of the viral genome from RNA to 
DNA during the infection process and the latter responsible for integrating the proviral 
DNA into the host cell genome. The env sequence encodes for both SU and TM subunits of 
the envelope glycoprotein. Additionally, retroviral genome presents non-coding cis-acting 
sequences such as, two LTRs (long terminal repeats), which contain elements required to 
drive gene expression, reverse transcription and integration into the host cell 
chromosome, a sequence named packaging signal (ψ) required for specific packaging of 
the viral RNA into newly forming virions, and a polypurine tract (PPT) that functions as 
the site for initiating the positive strand DNA synthesis during reverse transcription 
(Coffin et al. 1997). 
Additionally to gag, pro, pol and env, complex retroviruses, such as lentiviruses, have 
accessory genes including vif, vpr, vpu, nef, tat and rev that regulate viral gene expression, 
assembly of infectious particles and modulate viral replication in infected cells (Fig 2B).  
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Fig. 2. Retroviral genomes. Schematic representation of (A) MLV and (B) HIV-1 wild-type 
genomes representing simple and complex retrovirus, respectively. 
2. Cell line platforms for the production 
The establishment of retroviral and lentiviral producer cells, named packaging cell lines, has 
been based on the physical separation of the viral genome into different transcriptional units 
to minimize the risk of generating replication-competent particles (RCPs) (Fig. 3). Some of  
 
 
 
Fig. 3. Transcriptional units used for retroviral and lentiviral vector generation.  
(A) Three construct system used for (simple) retroviral vector and (B) four construct system 
used for third generation lentiviral vector production. Only the most relevant parts of the 
constructs are show; for further details see (Blesch 2004; Sinn et al. 2005).  
GOI: gene of interest; Prom_GOI: heterologous promoter and gene of interest. 
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these constructs are additionally engineered with heterologous sequences including: 
promoters (Dull et al. 1998) to support their independent expression or for improved safety, 
enhancers (Gruh et al. 2008) and stabilizing elements (Zufferey et al. 1999) to increase the 
overall levels of transcripts both in producer and target cells, hence increasing viral titers 
and transgene expression.  
2.1 Retroviral vectors 
For both retroviral and lentiviral vector production, different packaging systems, named 
generations, have been developed. Each new generation aimed at minimizing and reduce 
the risk of RCPs formation face to the previous one (Fig 3).  
In the case of vectors based on MLV or other simple retrovirus, the non-cytotoxicity of the 
viral genes has allowed the establishment of cell lines stably and constitutively expressing 
viral vectors. Table 1 lists some of the available retroviral vector packaging cell lines. 
The first packaging cells reported as so for simple retroviral vector production were 
established by providing the packaging functions (gag-pro-pol) with a retroviral genome 
where the packaging signal was deleted, thus preventing their incorporation into the viral 
particles (Cone and Mulligan 1984). However, a single event of homologous 
recombination was sufficient to restore replicative competence. This led to a second 
generation of retroviral packaging cells (Miller and Buttimore 1986), in which further 
modifications were introduced including the replacement of the 3’LTR and the second 
strand initiation site with the polyadenylation site of SV40. The third generation (Danos 
and Mulligan 1988) (Fig. 3A) further separates the construct that expresses gag-pro-pol 
from env, in a total of three independent transcriptional units. Although three 
homologous recombination events would be needed to restore replicative competence, 
which is very improbable, replicative competent viruses can still occur in third generation 
cell lines (Chong et al. 1998; Chong and Vile 1996). Therefore, additional improvements 
were made by means of decreasing the homology in the vector construct, using different 
LTR species to those used in the packaging functions (Cosset et al. 1995) or using 
heterologous promoters such CMV’s (Rigg et al. 1996; Soneoka et al. 1995). The most 
recently developed retroviral vector packaging cell lines are based on this third 
generation optimized system. Gag-pro-pol genes are expressed from a single construct 
driven by a heterologous promoter. Vector construct contains a cassette for transgene 
expression typically driven by the 5’LTR promoter; it additionally contains the packaging 
signal (ψ) and the initial gag sequence known to provide enhanced packaging (Bender et 
al. 1987). The envelope expression is supplied by a third independent construct usually 
driven by a heterologous promoter. The separation of the envelope in an independent 
transcriptional unit offers great flexibility for envelope exchange – pseudotyping – and for 
the use of genetically or chemically engineered envelope proteins, thus allowing 
changing, restricting or broadening vector tropism (McTaggart and Al-Rubeai 2002; Yu 
and Schaffer 2005). For simple retroviruses several envelope glycoproteins have been used 
including MLV’s amphotropic 4070A and 10A1 (Miller and Chen 1996), GaLV’s (gibbon 
leukemia virus) (Miller et al. 1991), RD114 from cat endogenous virus (Takeuchi et al. 
1994), HIV’s gp120 (Schnierle et al. 1997) and the G protein from vesicular stomatitis virus 
(VSV-G) (Burns et al. 1993). Since the proteins encoded by these sequences are usually 
non-toxic, except for the last one, they can be constitutively expressed such that simple 
retroviral vector packaging cell lines are typically stable and continuously producing 
systems. 
www.intechopen.com
Production of Retroviral and Lentiviral Gene  
Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus 
 
19 
Retroviral 
producer cell 
lines 
Cell origin Envelope 
Maximal 
Titers 
(I.P./mL) 
Vector
Packaging 
generation
Reference 
Ψ-AM Murine 
NIH 3T3 
Amphotropic 2.0 x 105 
MLV 
based
1st 
(Cone and 
Mulligan 1984) 
PA317 
Murine 
NIH 3T3 
Amphotropic 3.0 x 106 
MLV 
based
2nd 
(Miller and 
Buttimore 
1986) 
Ψ-CRIP Murine 
NIH 3T3 
Amphotropic 6.0 x 106 
MLV 
based
3rd 
(Danos and 
Mulligan 1988) 
PG13 
Murine 
NIH 3T3 
GaLV 5.0 x 106 
MLV 
based
(Miller et al. 
1991) 
Gp + 
envAm12 
Murine 
NIH 3T3 
Amphotropic 1.0 x 106 
MLV 
based
(Markowitz et 
al. 1988) 
HAII 
Human 
HT1080 
Amphotropic 1.0 x 107 
MLV 
based
(Sheridan et al. 
2000) 
FLY A4 
Human 
HT1080 
Amphotropic 1.0 x 107 
MLV 
based
(Cosset et al. 
1995) 
FLY RD18 
Human 
HT1080 
RD114 1.2 x 105 
MLV 
based
(Cosset et al. 
1995) 
Te Fly A 
Human 
Te671 
Amphotropic 1.0 x 107 
MLV 
based
(Cosset et al. 
1995) 
Te Fly Ga 18 
Human 
Te671 
GaLV 1.0 x 106 
MLV 
based
(Cosset et al. 
1995) 
CEM FLY 
Human 
CEM 
Amphotropic 1.0 x 107 
MLV 
based
(Pizzato et al. 
2001) 
293-SPA Human 293 Amphotropic 6.0 x 106 
MLV 
based
(Davis et al. 
1997) 
293 kat Human 293
Amphotropic 
Xenotropic 
10A1 
NR 
MLV 
based
(Farson et al. 
1999) 
Phoenix 
Human 
293T 
Amphotropic 1.0 x 105 
MLV 
based
(Swift et al. 
2001) 
Flp293 Human 293 Amphotropic 2.0 x 107 
MLV 
based
3rd with 
RMCE1 
technology
(Schucht et al. 
2006) 
293 FLEX Human 293 GaLV 3.0 x 106 
MLV 
based
(Coroadinha et 
al. 2006b) 
PG368 
Murine 
NIH 3T3 
GaLV 1.0 x 106 
MLV 
based
(Loew et al. 
2009) 
Table 1. Packaging cell lines for retroviral vector manufacture (1 – RMCE – Recombinase 
Mediated Cassette exchange; NR – Not reported: the titers reported for these packaging cells 
are expressed in terms of reverse transcriptase activity, which the correlation with infectious 
titers depends on the cell system.)   
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Retroviral vectors have been based on several viruses including avian, simian, feline and 
murine retroviruses, being the latter (MLV) the most used. As so, the majority of the 
retroviral vector packaging cell lines established were murine derived, being NIH/3T3 
the most widely employed. However, it was rapidly found that the presence of 
galactosyl(α1-3)galactose carbohydrate moieties produced by murine cells in retroviral 
envelope lead to its rapid detection and inactivation by the human complement system 
(Takeuchi et al. 1994; Takeuchi et al. 1997; Takeuchi et al. 1996). Nowadays, murine cells 
are being replaced by human cell lines, to reduce the possibility of endogenous retroviral 
sequences packaging and also to improve vector half-life in vivo (Cosset et al. 1995).  
Establishing a producer cell line involves at least three transfection and clonal selection 
steps, taking a time-frame of around one year which constitutes a major drawback in stable 
cell line development (see section 3.1). Yet, this process is undertaken for each new 
therapeutic gene and/or different envelope protein required (for changing vector tropism). 
On the other hand, high-titer packaging cells development has been based on an efficient 
method to facilitate the selection of a high producer cell clone in which a selectable marker 
gene is inserted in the vector construct downstream of the viral genes, so they are translated 
from the same transcript after ribosomal reinitiation (Cosset et al. 1995). This strategy, 
however, although very efficient for screening stable integration and/or high level long-
term viral genome expression, raises considerable problems in therapeutic settings 
including immune response against the selection (foreign) gene product(s) (Liberatore et al. 
1999). Therefore, a new generation of retrovirus packaging cell lines based on cassette 
exchange systems that allow for flexible switch of the transgene and/or envelope, as well as 
selectable marker(s) excision, were developed (Coroadinha et al. 2006b; Loew et al. 2004; 
Persons et al. 1998; Schucht et al. 2006; Wildner et al. 1998). 
Schucht et al (2006) and Coroadinha et al (2006) established modular cell lines, based on targeted 
genome integration allowing to obtain rapidly high-titer retroviral producer cells (Figure 4).  
 
 
IRES
LTR
ψ
Reporter Gene hygtk
(A)
LTR
IRES/P
Transgene ATG
(B)
LTR
ψ
∆neo∆neo
LTR
 
 
Fig. 4. Schematic representation of the modular cell lines based on the recombinase 
mediated cassette exchange (RMCE) technology. (A) Integrated retroviral transgene cassette 
harboring a marker gene and (B) targeting therapeutic transgene plasmid allowing a fast 
exchange and establishment of a new retroviral producer cell. 
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Two cell lines were created; Flp293A and 293 FLEX, both derived from 293 cells. The former 
pseudotyped with amphotropic and the latter with GaLV envelopes. Recently, a PG13-based 
murine producer cell line was also established using this strategy (Loew et al. 2009). A 
favorable chromosomal site for stable and high retroviral vector production is first identified 
and tagged. Due to the presence of two heterologous non-compatible FRT sites flanking the 
tagged retroviral genome, the subsequent re-use of this defined chromosomal site by means 
of RMCE is than performed to express a therapeutic gene. In order to select cell clones that 
underwent correct targeted integration reaction, the targeting viral vector contains a start 
codon that complements a transcriptionally inactive ATG-deficient selection marker after 
recombination.  
The modular producer cell lines present several advantages: they are safer since integration 
of the vector within the packaging cell line was identified, the duration of the entire 
development process is much reduced as there is no need for screening and, in addition, 
production conditions are favorable due to the possibility of pre-adaptation of the master 
cell line to culture conditions and media. Thus, therapeutic virus production from bench to 
bedside becomes safer, faster, and cheaper (Coroadinha et al. 2010). 
2.2 Lentiviral vectors 
Similarly to retroviral vectors, the design of lentiviral vector packaging systems has evolved 
to minimize the risk of RCPs generation towards maximum safety. Currently, three 
generations of lentiviral vectors are considered. The first-generation (Naldini et al. 1996) 
closely resembles the three plasmid packaging system of simple retroviruses, except for the 
fact that the gag-pol expression is driven by a heterologous promoter instead of the viral 
LTR; additionally, the gp120 HIV-1’s envelope was replaced by VSV-G’s. However, this 
system contained all the necessary sequences for the generation of RCPs with three 
homologous recombination events which, although improbable, could not be accepted for a 
human and potentially lethal pathogen. 
In the second generation (Zufferey et al. 1997), the three plasmid system was maintained 
but all the accessory genes were deleted including vif, vpr, vpu, and nef. The third 
generation (Fig. 3B) allowed for a tat independent lentiviral vector expression by 
engineering a chimeric 5’LTR with a heterologous viral promoter/enhancer, such as 
CMV’s (cytomegalovirus) or RSV’s (Rous sarcoma virus) (Dull et al. 1998); rev 
complementation was separately provided in trans, thus this system has a total of four 
constructs. A schematic representation of the third generation system is shown in Fig. 3B. 
Gag-pro-pol genes are expressed from a CMV promoter and none of the accessory or 
regulatory proteins is present in this construct. Only rev accessory gene is maintained but 
is provided by a nonoverlapping plasmid. Vector cassette for transgene expression is 
driven by a heterologous promoter, as virus LTRs were partially deleted. Similarly to 
simple retroviruses, the transgene vector construct additionally contains the packaging 
signal (ψ) and the initial sequence from gag. The envelope cassette encodes typically, but 
not necessarily, for VSV-G envelope glycoprotein. 
The development of a fourth generation of lentiviral vectors, rev independent, has also been 
claimed by means of replacing RRE (rev responsive element) with heterologous viral 
sequences or by codon-optimization (Bray et al. 1994; Delenda 2004; Kotsopoulou et al. 2000; 
Pandya et al. 2001; Roberts and Boris-Lawrie 2000). However, its use is not widespread 
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since, contrary to the other generations of lentiviral vectors, these packaging systems have 
not been made available for the research community; also the reported titers are typically 
one to two logs bellow the maximum titers obtained with the second or third generation 
systems.  
In addition to HIV-derived, other lentiviral vectors have been developed and reported to 
retain identical features to those of HIV’s based, including the ability to transduce non-
dividing cells, high titers production, and the possibility to be pseudotyped with different 
envelope glycoproteins. These include lentiviral vectors based on SIV (simian 
immunodeficiency virus) (Pandya et al. 2001; Schnell et al. 2000), BIV (bovine 
immunodeficiency virus) (Matukonis et al. 2002; Molina et al. 2004), FIV (feline 
immunodeficiency virus) (Poeschla et al. 1998; Saenz and Poeschla 2004) and EAIV 
(equine infectious anaemia virus) (Balaggan et al. 2006; Mitrophanous et al. 1999; Stewart 
et al. 2009). Most of non-HIV derived lentiviral vectors have been reported to be tat and 
sometimes rev independent, thus falling in the 3rd or 4th generation of packaging systems. 
For clinical trials purposes, both second and third generation lentiviral vector systems 
were reported although only HIV-1 and EAIV derived vectors have been used (Schweizer 
and Merten 2010). 
Contrarily to simple retroviral vectors, the cytotoxicity of some of the lentiviral proteins 
has hampered the establishment of stable cell lines constitutively expressing vector 
components. Therefore, the majority of the reported packaging cells for lentivirus 
manufacturing have been based on inducible systems that control the expression of the 
toxic proteins (for further details see section 3.1). Nevertheless, it is worth notice that 
transient production is still the main mean for lentiviral vector generation for both 
research and clinical purposes. Table 2 summarizes some of the available (stable) 
lentiviral vector packaging cell lines. 
Except for the systems reported by and Ni et al. (2005), all the packaging cell lines for 
lentiviral vector production have been based on human 293 cells transformed with 
oncogenes such as the SV40 (simian vacuolating virus 40) large T antigen – 293T – or the 
Nuclear Antigen of Epstein-Barr Virus – 293EBNA.  
For clinical application human 293 and 293T cells have been the exclusive cell substrates 
(Schweizer and Merten 2010). However, safety concerns arise from the fact that 90% of non-
coding mobile sequences of the human genome are endogenous retrovirus and although 
most of them are defective, because of mutations accumulation, some are still active 
(Zwolinska 2006). Therefore, using human cell lines for the production of human 
retroviruses increases the chances of replicative-competent particles generation by 
homologous recombination (Pauwels et al. 2009). Also, the possibility of contamination with 
other human pathogens during the production process, poses additional hindrances to the 
use of human cells for biopharmaceuticals production, viral or not. In this context, the use of 
non-human cells would be strongly recommended, although the different glycosylation 
patterns of the envelope proteins could be an obstacle. For research purposes other human 
or monkey derived cells were tested (other 293 derived clones, HeLa, HT1080, TE671, COS-
1, COS-7, CV-1), although most of them showed reduced vector production titers. Yet, COS-
1 cells have shown to be capable of producing 3-4 times improved vector quality (expressed 
in infectious vector titer per ng of CA protein, p24), comparing with 293T cells (Smith and 
Shioda 2009).  
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Lentiviral 
packaging 
cell line 
Cell 
origin 
Envelope
Maximal 
Titers 
(I.P./mL)
Vector
Packaging 
generation1
Observations Reference 
SODk 
Human 
293T 
VSV-G 1.0 x 107
HIV-1 
based
2nd Tet-off 
(Cockrell et 
al. 2006; 
Kafri et al. 
1999; Xu et 
al. 2001) 
293G 
Human 
293T 
VSV-G - 
HIV-1 
based
2nd Tet-off 
(Farson et 
al. 2001) 
STAR 
Human 
293T 
Ampho
GaLV 
RD114
1.2 x 107
1.6 x 106
8.5 x 106
HIV-1 
based
2nd 
Continuous system. 
Codon-optimized gag-
pol 
(Ikeda et al. 
2003) 
NR 
Human 
293 
VSV-G 3.5 x 107
HIV-1 
based
2nd 
Tet-off.
Three level cascade gene 
regulation system: TRE 
→ tat+rev → VSV-
G+Gag-Pol. Codon-
optimized gag-pol 
(Ni et al. 
2005) 
REr1.35 
Human 
293T 
VSV-G 1.8 x 105
HIV-1 
based
3rd 
Ecdysone inducible 
system. Codon-
optimized gag-pol 
(Pacchia et 
al. 2001) 
293SF-
pacLV 
Human 
293 
EBNA
VSV-G 3.4 x 107
HIV-1 
based
3rd Tet-on 
(Broussau 
et al. 2008) 
PC48 
Human 
293T 
VSV-G 7.4 x 105
EIAV 
based
3rd Tet-on 
(Stewart et 
al. 2009) 
SgpG109 
Human 
293T 
VSV-G 1 x 105
SIV-
based
3rd 
Ponasterone inducible 
system. Codon-
optimized gag-pol 
(Kuate et al. 
2002) 
GPRG 
Human 
293T 
VSV-G 5 x 107
SIV-
based
3rd 
Introduction of vector 
by concatemeric array 
transfection. Tet-off 
(Throm et 
al. 2009) 
Table 2. Packaging cell lines for lentiviral vector manufacture (1 – No lentiviral packaging 
cell line was developed based on the first generation lentiviral vector system.  
Tet-on/ Tet-off – tetracycline inducible system; tet-on becomes active upon tetracycline  
(or an analogous molecule such as doxycycline) is added and tet-off is activated by 
tetracycline removal.  NR: not reported) 
3. Bioreaction platforms and production media 
3.1 Stable vs. transient expression  
Production platforms for lentiviral and retroviral vectors have been restrained to 
mammalian cells, typically murine or human derived, which are transfected with gag-pol the 
packaging functions, vector (transgene) and envelope constructions. This can be based on a 
short-term transfer of the viral constructs, known as transient production, into exponentially 
growing cells followed by 24-72 hours vector production and harvesting, or by their stable 
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integration and constitutive expression into the host cell genome, for continuous production 
(Fig. 5).  
Transient production, makes use of transfection methods to introduce the viral 
constructions, commonly cationic agents that complex with the negatively charged DNA, 
thus allowing it to be up-taken by the cell via endocytosis (Al-Dosari and Gao 2009). From 
those, polyethylenimine (PEI) (Boussif et al. 1995) is probably the less expensive, one of the 
most efficient and the most widely used in the current protocols (Schweizer and Merten 
2010; Segura et al. 2010; Toledo et al. 2009). Others methods such as calcium phosphate 
precipitation (Jordan and Wurm 2004; Mitta et al. 2005) and cationic lipids complexation 
including LipofectAMINE® and FuGENE®, have also been used, although at small-scale 
production or for research purposes only since, these are either difficult to scale-up or very 
expensive. Alternatively, viral infection has also been developed and validated namely for 
lentiviral vector production, using baculoviruses as transfection agents (Lesch et al. 2008). 
However, the additional downstream work to separate lentiviral vector and baculoviruses 
to achieve clinical-grade viral preparations standards, as well as the final titers reported 
(Lesch et al. 2011) reduced the competitiveness of lentiviral vector production using 
baculoviruses over plasmid DNA transfection methods.  
 
 
Fig. 5. Stable vs. transient viral vector production. (A) Stable and continuous production 
from cell lines constitutively expressing viral vector transgene, gag-pro-pol and env; vector 
titers are nearly dependent on cell density until the end of the exponential phase of cell 
growth. (B) Transient production after plasmid transfection of viral vector transgene, gag-
pro-pol and env; high titers are obtained usually between 24 to 72 hours post-transfection, 
after which a pronounced decrease occurs, typically due to cell death. 
Stable production relies on cell substrates in which the viral constructs where separately 
integrated into the cell genome, thus allowing their constitutive expression. Typically, the 
packaging functions are first inserted and after clonal selection of a high-level gag-pol 
expression, the envelope construction is then inserted and a second round of clonal selection 
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is performed. At this point, a packaging cell line is established, in principal supporting the 
packaging of any viral vector (retroviral or lentiviral, depending on the gag-pro-pol 
functions). Finally, the transgene is introduced. If non-SIN vectors are used, this can be 
achieved directly by viral infection; otherwise, chemical transfection methods as those 
described above followed by stable integration and selection are required and equally 
suitable. Cosset and co-workers (1995) reported a very efficient method in which viral vector 
construct containing a (selectable) marker gene is firstly inserted in nude cells, facilitating 
the screening for stable integration and high-level long term expression (Cosset et al. 1995). 
This scheme was demonstrated to allow for the establishment of high-titer human derived 
retroviral vector packaging cell lines. Additionally, it permits high-titer retroviral vector 
production from single copy integration allowing for modular cell lines development, 
flexible platforms for transgene and/or envelope exchange (Coroadinha et al. 2006b; 
Schucht et al. 2006) (Fig. 4). Moreover, it allows optimization of the stoichiometry of the 
packaging constructs, maximizing viral titers and vector preparation quality, expressed by 
the ratio of infectious particles to total particles, which has a drastic impact on vector 
transduction efficiency a crucial parameter for clinical purposes (Carrondo et al. 2008).  
Stable retroviral vector cell line development is a tedious and time consuming process 
which can take up to one year for a fully developed and characterized cell platform. 
However, it is compensated by obtaining continuously producing and highly consistent cell 
systems, prone to single-effort bioprocess and product characterization, a critical 
consideration for market approval. 
Transient production is undoubtedly faster, when compared to the time frame necessary to 
develop a stable packaging cell line, presenting very competitive titers (up to 107 infectious 
vector per mL). Yet, for clinical purposes, continuous production by stable cell lines is highly 
desirable, since transient systems are difficult to scale-up, time and cost-ineffective at large 
scales and, more importantly, are unable to provide a fully characterized production 
platform with low batch-to-batch variability of the viral preparations. Therefore, transient 
production is unlikely to be of value after the transition from clinical to market. Retroviral 
vector manufacture, including those used in clinical trials, has been making use of stable 
and continuous cell lines for more than ten years (Cornetta et al. 2005; Eckert et al. 2000; 
Przybylowski et al. 2006; Wikstrom et al. 2004). However, the establishment of stable 
lentiviral vectors packaging cell lines has remained a challenge due to the inherent 
cytotoxicity of the lentiviral protease which has prohibited its constitutive expression 
(Schweizer and Merten 2010). It is well established that numerous HIV-1-encoded proteins 
are capable of causing cell death, including tat, nef, env, vpr and the protease (PR) (Gougeon 
2003); from those, only the protease is still required in the current packaging systems. HIV 
protease mediates its toxicity in vitro and in vivo, by cleaving and activating procaspase 8, 
leading to mitochondrial release of cytochrome c, activation of the downstream caspases 9 
and 3 and lastly, nuclear fragmentation (Nie et al. 2007; Nie et al. 2002). Ikeda and co-
workers have reported the development of a 293T derived cell line, STAR, stable and 
continuously producing LV using an HIV-1 codon optimized gag-pol (Ikeda et al. 2003). 
However, significant titers could only be obtained by MLV-based vector transduction of the 
optimized gag-pol. This procedure raises biosafety issues, since it increases the chances of 
generating replicative-competent particles by homologous recombination and, posing 
further concerns of co-packaging (Pauwels et al. 2009).  
At a laboratory scale, transient production by plasmid transfection has been the first choice 
to cope with the cytotoxic proteins. For larger-scale production purposes, conditional 
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packaging systems have been developed in which the expression of those is under the 
control of inducible promoters (Broussau et al. 2008; Farson et al. 2001; Kuate et al. 2002; 
Pacchia et al. 2001; Stewart et al. 2009). However transient transfection systems are, as 
discussed above, difficult to scale-up and do not fulfill adequate batch-to-batch variability 
standards; and, although the clinical trials currently using lentiviral vectors have been 
provided exclusively with transiently produced batches (Schweizer and Merten 2010), it is 
unlikely that a transient based systems will be approved when going from clinical to 
market. Conditional systems, on the other hand, require the addition/removal of the 
induction agents cumbering the production and requiring further down-stream stringency 
in processing of the viral preparations. 
3.2 Stirred bioreaction vs. adherent cultures 
It is widely accepted that stirred bioreaction systems using suspension cultures offer more 
advantages from the bioprocess view-point when compared to those under static/adherent 
conditions. The most evident advantage is the higher volumetric productivity, since 
suspension cultures in stirred systems present increased ratios of cell number per volume of 
culture medium. Because of this, they are easier to scale-up with less space requirements; 
the agitation allows for homogeneous cells suspension preventing the formation of chemical 
(nutrient, waste products), physical (pH, oxygen, carbon dioxide) and thermal gradients, 
thus maximizing the productivity potential of the culture (Sadettin and Hu 2006).  
The first suspension system reported for high-titer retroviral vector production was based 
on a T-lymphoblastoid cell line using a third generation packaging construct, producing 
MLV derived retroviral vectors pseudotyped with amphotropic envelope: CEMFLYA cells 
(Pizzato et al. 2001). These cells were able to produce in the range of 107 infectious units per 
mL and, the potential for scaled up vector production was demonstrated by continuous 
culture during 14 days in a 250 mL spinner flask. After CEMFLYA, other high-titer 
suspension cells were reported, namely suspension-adapted 293GPG cells producing MLV 
retrovirus vector pseudotyped with the vesicular stomatitis virus G (VSVG) envelope 
protein and expressing a TK-GFP fusion protein in a 3L acoustic filter-based perfusion 
bioreactor (Ghani et al. 2006). Another major landmark was achieved when the same group 
published for the first time retroviral vector production in suspension and under serum-free 
conditions (Ghani et al. 2007) (see section 3.4.1). Following retrovirus, lentiviral vector 
manufacture using suspension cultures has also been recently reported both for 
transfection-based transient production (Ansorge et al. 2009), as well as, for stable 
production using (inducible) packaging cell lines (Broussau et al. 2008). 
Despite the advances in the development of suspension cultures for stirred tank bioreactors 
and its clear advantage from the bioprocess view-point, retroviral and lentiviral vector 
manufacture for clinical batches has mainly been based on adherent static and preferably 
disposable systems, including large T-flasks, cell factories and roller bottles (Fig. 6) (Eckert 
et al. 2000; Merten et al. 2011; Przybylowski et al. 2006; Wikstrom et al. 2004). A good 
example is retroviral vector production at the National Gene Vector Laboratory, Indiana 
University, (Indianapolis, IN), a US National Institutes of Health initiative that has as main 
mission provide clinical grade vectors for gene therapy trials (Cornetta et al. 2005). Also for 
clinical-grade lentiviral vector production, the bioreaction system of choice has been Cell 
Factory or equivalent multitray systems (Merten et al. 2011; Schweizer and Merten 2010).  
These systems allow for 10 to 40 L vector production under GMP conditions, meeting the 
needs for initial trials, where usually a reduced number of patients are involved. In the 
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future, if lentiviral and retroviral vector Gene Therapy products reach the market, it is still 
not clear if such systems will continue to be used. In fact, several restrictions arise from the 
use of disposable systems and bioreactors including the increase in the costs of solid waste 
disposal and consumables, in addition to low scalability and the single-use philosophy itself 
(Eibl et al. 2010). However, the low infectivity stability of retro and lentiviral vectors has 
hampered the perspective of the “thousand-liter” production systems’ for further storage. 
Nevertheless, significant efforts are being made to overcome this drawback including, at the 
bioprocess level, by developing storage formulations (Carmo et al. 2009a; Cruz et al. 2006) 
and at the viral vector design level, by developing mutant vectors with increased infectivity 
stability (Vu et al. 2008). 
 
 
Fig. 6. Culture systems used for retroviral and lentiviral vector manufacture. Stirred tank 
bioreactor (A) vs. adherent disposable systems, T-flasks (B), roller bottles (C) and (D) cell 
factories. 
3.3 Bioreaction physicochemical parameters 
The cell culture parameters used in the bioreaction may have a profound effect on the virus 
titer by affecting the cellular productivities, vector stability or both. Several studies have 
been performed analyzing the impact of physicochemical parameters such as pH, 
temperature, osmolarity, O2 and CO2 concentrations. The optimal cell culture parameters 
have been shown to be producer cell line and viral vector dependent. 
The optimal pH range for retroviral vector production was found to be between 6.8 and 7.2 
for FLY RD18 and Te FLY A7; outside this range the cell specific productivities were 
considerable lower (McTaggart and Al-Rubeai 2000; Merten 2004), while the retroviral 
vector was observed to be stable between pH of 5.5 and 8.0 in ecotropic pseudotyped 
vectors (Ye et al. 2003). Both retroviral vectors (MLV derived) and lentiviral vectors (HIV-1 
derived), VSV-G pseudotyped, were stable at pH 7. The half-lives of both viral vectors at pH 
6.0 and pH 8.0 markedly decrease to less than 10 minutes (Higashikawa and Chang 2001). 
The viral half-life is also dependent on the temperature: at lower temperatures the vector 
decay kinetics are lower (Le Doux et al. 1999). Therefore one strategy explored in the 
production of retroviral vectors has been the reduction of the culture temperatures (28-
32ºC). Some authors reported increases in vector production at lower temperature (Kaptein 
et al. 1997; Kotani et al. 1994; Le Doux et al. 1999; Lee et al. 1996). The reduction of the 
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culture temperature from 37ºC to 32ºC extends vector stability allowing for the 
accumulation of more infectious virus and thus, increasing the volumetric titers. However, 
the increments are not always very significant as the temperature affects also the cell specific 
yields negatively. The improvement in the viral volumetric titer will be only observed if, the 
increase in the viral half-life is higher than the decrease in the cell specific production rate 
(Le Doux et al. 1999). Additionally, the viral vector inherent stability was also demonstrated 
to be lower when the viral vector was produced at 32ºC instead of 37ºC (Beer et al. 2003; 
Cruz et al. 2005). It was shown that the culture temperature affected the lipid viral 
membrane composition namely, the cholesterol content. The increase in cholesterol content 
was demonstrated to be inversely proportional to retroviral stability (Beer et al. 2003; 
Coroadinha et al. 2006c). Since enveloped virus, such as retrovirus and lentivirus, bud out of 
the host cells, they take part of the host cell lipidic membrane. Thus, the origin of the 
producer cell will have a pronounced effect on the viral particle stability and explain the 
discrepant results obtained for virus produced in different cells and at different 
temperatures. For PA317 cells, decreasing the production temperature from 37ºC to 32ºC 
resulted in an increase of 5-15 fold in the vector titers (Kaptein et al. 1997) while for PG13 
lower titers were obtained (Reeves et al. 2000). The viral vector envelope glycoproteins also 
affect the viral particle inherent stability increasing the complexity and diversity of factors 
involved in the viral stability. Comparing lentiviral and retroviral vectors it was generally 
observed that HIV-1 derived vectors are more stable at 37ºC and at higher temperatures 
than MLV derived vectors (Higashikawa and Chang 2001). 
Augmenting the media osmolarity was also shown to be a valid strategy to increase retroviral 
vector titers in Te FLY A7 (Coroadinha et al. 2006c). This increment was correlated with higher 
cell specific productivities and higher inherent viral stability. The high osmotic pressure 
altered the cellular and viral envelope lipid membrane composition. High osmotic media were 
tested showing to induce a decrease in the cholesterol to phospholipids ratio in the viral 
membrane and thus conferring higher stability to the viral vectors produced (Coroadinha et al. 
2006c). These results, together with the studies of production at lower culture temperatures, 
strengthen the importance of lipid metabolism in the production of enveloped virus.   
CO2 gas concentration in the cultures did not affect virus production in packaging cell lines 
(Kotani et al. 1994; McTaggart and Al-Rubeai 2000). The dissolved oxygen levels used are 
between 20-80% and within this range do not affect viral production unless they became 
limiting to cell growth (Merten 2004). 
3.4 Media composition and cell metabolic bottlenecks 
Retroviral and lentiviral vector titers obtained in the production prior to purification are in 
the range of 106 to 107 infectious particles per mL of culture medium. Considering the 
average amount needed to treat a patient in a clinical trial, in the order of 1010  infectious 
vectors (Aiuti et al. 2009; Cavazzana-Calvo et al. 2000; Ott et al. 2006), around 10-100 L of 
culture volume can be previewed for each patient. Also, viral preparations are typically 
characterized by low ratios of infectious particles to total particles (around 1:100) which 
further reduce the therapeutic efficiency of the infectious ones (Carrondo et al. 2008). 
Additionally, these vectors are extremely sensitive losing their infectivity relatively fast, the 
reported half-lives are between 8-12 hours in cell culture supernatant at 37ºC (Carmo et al. 
2009b; Carmo et al. 2008; Higashikawa and Chang 2001; Merten 2004; Rodrigues et al. 2009). 
Thus, the productivity performance of retroviral and lentiviral vector producing systems is 
below the therapeutic needs. 
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The problems of low titers, short half-life and low ratios of infectious particles to total particles 
have been subject of intensive bioprocess research. However, the infection with wild type 
retroviruses, in particular HIV-1, is typically chronically and characterized by persistent but 
low titers of the infectious agents in the blood stream, with high amounts of non-infectious 
particles contaminants and with equivalently low half-lives (Perelson et al. 1996; Rusert et al. 
2004). Therefore, retrovirus and lentiviral manufacture starts in disadvantage – when 
compared to other viral vectors – in what concerns to such parameters. Several strategies have 
been attempted to circumvent these “natural” drawbacks in packaging cell lines, including 
engineering mutant vectors with improved resistance features and understanding and 
optimizing the metabolic pathways leading to improved productivities. Studying the 
metabolic features driving to high titer performances has been one important work lines of 
research. Therefore, this section will mainly focus on the metabolic bottlenecks of viral vector 
production. 
3.4.1 Serum supplemented vs. serum-free media 
The supplementation of mammalian cell culture media with animal sera has been common 
practice in biomedical and biotechnological research, since it provides critical nutrients and 
factors that support cell growth and proliferation. However, the ill-defined composition and 
high batch-to-batch variability of serum together with its potential source of contaminations, 
hinders safety and standardization of cell cultures, making it a highly undesirable 
supplement in the production of biopharmaceuticals (Falkner et al. 2006). Also, in the case of 
retroviral and lentiviral vectors, serum needs to be removed from the medium and/or viral 
preparations to prevent immunological responses in the patients. 
Retroviral and lentiviral vector manufacture has been reported to rely on considerable 
amounts (5-10% (v/v)) of animal sera in the culture medium; although some authors 
reported improved titers in short-term serum-free productions (Gerin et al. 1999a; 
McTaggart and Al-Rubeai 2000), the issue of serum dependence for retroviral and lentiviral 
vector production will be next discussed in the perspective of long-term cultures. The 
majority of the latest generation of packaging cell lines, specially the HEK293 (human 
embryonic kidney) derived ones, seem to require high concentrations of serum in the 
culture medium to support elevated viral productivities for long term culture (Chan et al. 
2001; Gerin et al. 1999a; Gerin et al. 1999b; Pizzato et al. 2001; Rodrigues et al. 2009).  
The need of serum for retroviral and lentiviral vector production has been mainly associated 
with the lipidic needs of packaging cell lines. Unless other supplements are added, serum is 
the only lipid source of the culture medium and, although cells should be able to sense lipid 
absence in the culture medium and activate biosynthetic pathways to stand up to lipid 
deprivation, the activation of lipid de novo synthesis may take hours or days, depending on 
the cell type (Alberts et al. 1974; Spector et al. 1980). In some cases, cells can no longer 
synthesize certain lipids (Seth et al. 2005). Membrane lipids are active players in the complex 
process of retroviral assembling, and pseudotyping that takes place at the host cell 
membrane, in which interactions of membrane lipid rafts select both envelope and core 
proteins, recruiting later the other viral components by cooperative interaction. The 
production of infectious particles is known to rely on the efficiency of this process, which is 
dependent upon a delicate equilibrium of lipid type and amounts, easily disturbed by lipid 
deprivation (Briggs et al. 2003). Therefore, changes in serum concentration that disturb cell 
membrane lipid composition will ultimately affect viral particle membrane properties 
(Rawat et al. 2003) possibly resulting in a higher production of non-infectious particles. In 
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fact, it has been not only demonstrated that lipids are one of the main serum components 
correlated with high retroviral infectious vector titers but also, that the reduction of serum in 
the culture medium affects infectious titers only, i.e. the total number of particles produced 
remained unaltered (Rodrigues et al. 2009). Indeed, high-titer production of retroviral and 
lentiviral vectors under serum-free conditions has only been achieved in the presence of 
lipid supplements, lipid carriers and lipoproteins addition (Broussau et al. 2008; Ghani et al. 
2007). 
The work done so far, addressing the issue of serum supplementation and infectious vector 
production, has mainly been focused on retroviral vectors, less attention has been paid to 
serum/lipid requirements in lentiviral vector production. Of notice is the work developed 
by B. Mitta et al (2005) in which optimal lentiviral production parameters were established, 
resulting in up to 132-fold improved productivities, and quality. The later is defined as the 
viral infectious titer (reflecting the number of transduction-competent lentiviral particles) 
relative to the number of total physical lentiviral particles produced (analysed by the levels 
of p24). A reduced-serum formulation was used and supplemented.  Among others, lipid 
supplementation, included cholesterol, lecithin and chemically defined lipid concentrates. 
The lipid supplements were identified as the main responsibles for the improved viral 
productivities obtained. 
In the case of lentiviral vectors, the short-term production periods associated with either the 
transient or conditional productions have not elucidated the extent of serum dependence in 
the production of high-infectious vector titers. Yet, the large majority of the current 
protocols for the production of lentiviral vectors still make use of 5 to 10% (v/v) of serum in 
the culture medium and up to now, only two publications have reported the production of 
lentiviral vectors under serum-free conditions (Ansorge et al. 2009; Broussau et al. 2008), 
both of them requiring lipid supplementation.  
More recently, studies on the effects of adapting retroviral vector packaging cell lines to 
serum deprivation conditions and how it impacts infectious vector production have been 
performed. These studies identified differences in cell lipid metabolism as a requirement 
needed by the packaging cells to be able to adapt to serum deprivation: cells capable of 
activating de novo lipid biosynthesis under serum withdrawal, particularly cholesterol, are 
able to be adapted to serum deprivation without significant loss of infectious vector titer 
production. On the other hand, cells facing serum removal from the culture medium that are 
unable to activate lipid biosynthesis – HEK293 – lose infectious titer productivity after a few 
passages (Rodrigues et al., 2011). In this context, it should be noticed that long term serum-
free production of retro and lentiviral vectors reported so far has been based not only in 
lipid supplemented media but also on oncogene transformed 293 cells, namely 293T, 
transformed with SV40 large T antigen (T-Ag) and 293 EBNA, transformed with Nuclear 
Antigen of Epstein-Barr Virus. These cells exhibit very different physiological features when 
compared to their non-transformed counterparts, 293, potentially facilitating serum-
independence for vector production.  For instance, SV40 transformed cells were shown to 
require minimal serum amounts or no serum at all, in the culture medium in order to 
proliferate. T-Ag expression is known to allow to overcome growth arrest mediated by 
contact inhibition and provide to the transformed cells an anchorage independent 
phenotype (Ahuja et al. 2005). Additionally, T-Ag expression drives even quiescent cells to 
the S-Phase (Ahuja et al. 2005), potentially providing raw material for viral replication. 
Besides those changes mentioned above, not much is known about the long-term 
physiological modifications induced by T-Ag and EBNA transformation. However, it is 
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possible that some of those changes target lipid biosynthetic pathways, given that oncogenic 
neoplastic transformation is typically characterized by an increase in lipid biosynthesis and 
turnover (Barger and Plas 2010; Swinnen et al. 2006). In conclusion, the major metabolic 
hinge between serum and high titers has been demonstrated to be the lipids and cellular 
lipid metabolism.  
3.4.2 Sugar carbon source 
Glucose has been the traditional sugar source employed in animal cell culture media and 
thus, the most used in the production of retroviral and lentiviral vectors. Together with 
glutamine, glucose is the major energy and carbon source in the culture medium. It is also 
the universal carbohydrate in animal cell culture, since glucose cellular transporters are 
present in the majority of the mammalian cell types. However, glucose is rapidly consumed 
and inefficiently metabolized to lactate which, per se, is toxic to the cell. Concentrations of 
lactate above 5 mM can inhibit cell growth of Te Fly Ga18 cells and retroviral production 
(Merten et al. 2001).  
The use of alternative sugar sources to glucose is a possible strategy to decrease lactate 
production. Indeed, the use of fructose and galactose was shown to improve the retroviral 
production in Te FLY A7, Te FLY Ga18, PG13 and Tel CeB cell lines (Coroadinha et al. 
2006a; Merten 2004). The lactate production decreased 2 to 6 fold in galactose and fructose 
media and the vector titers increased up to 8 fold. Both galactose and fructose consumption 
rates were lower than glucose in Te Fly A7, possible due to lower specificity of the sugar 
transporters expressed in these cells. The best results in terms of vector titers were obtained 
at high concentrations of fructose (15-25 g/L) (Coroadinha et al., 2006, Merten, 2004). 
Additionally to the metabolic shift induced by an alternative carbon source, an effect of high 
osmotic pressure can also be of relevance in the improvement of viral titers (see section 3.3). 
The increment of infectious titers observed at high sugar concentrations in Te Fly A7 was 
confirmed to be the result of higher cell specific productivities, higher vector stability and 
lower production of defective non-infective particles (Coroadinha et al., 2006a and 2006b) 
(Table 3).  
 
Medium 
Osmolality
(mOsm/kg)
Cell 
Productivity 
(I.P. cells-1.h-1)
Virus Half-
Life (h) 
Cholesterol/Phospholipid 
molar ratio in viral particles 
Glucose 25 mM 335 0.18 ± 0.01 8 ± 0.7 0.53±0.03 
Glucose 25 mM 
+ sorbitol 
450 0.80± 0.09 14± 1 0.33±0.01 
Fructose 140 
mM 
450 1.0± 0.1 14±2 0.30±0.01 
Table 3. Effect of alternative sugar sources and media osmolality in retroviral vector 
production. Te Fly A7 producer cells were used in this study. Sorbitol is a non-ionic osmotic 
agent, non-metabolized by the cells. 
Further metabolic studies were performed using 13C-NMR spectroscopy indicating changes 
in the lipid metabolism, namely higher synthesis of phospholipids (Coroadinha et al., 2006 
and Amaral et al., 2008). These results show that packaging cell line metabolism deeply 
influences the productivity performances, in particular lipid biosynthesis, thus suggesting it 
to be an important target for further improve retroviral and possibly lentiviral vector titers. 
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No studies with alternative sugar sources have been reported with lentiviral vectors. 
Nevertheless, the above studies were performed with, Te671 and NIH 3T3 cells and most 
lentiviral vectors are produced in 293 derived cells. 
4. Conclusions and outlook 
Murine leukemia virus (MLV) derived vectors were the first viral vectors used in clinical 
trials and remain among the preferentially used vehicles for gene therapy applications due 
to their advantages relatively to other vectors. Lentiviral vectors have been developed more 
recently. From the therapeutic perspective they present the additional advantage of 
transducing non-dividing cells. From the manufacturing perspective lentiviral vectors 
present however, an additional difficulty as they contain cytotoxic proteins, requiring either 
the use of transient transfection or inducible systems. Both lentiviral and retroviral vectors 
are derived from virus belonging to the retroviridae family sharing many characteristics in 
terms of genome, biochemistry, structure and viral cycle. Thus many of the metabolic 
constraints in their production are common and reviewed herein.  
The success of the application of retroviral vectors in phase I and II clinical trials is now 
moving the prospects to phase III trials. This will create momentum to increase the efforts in 
research related with retroviral vectors development and production due to the large 
amounts of vectors needed, and the stringent demands by the regulatory agencies. 
Lentiviral vectors in particular possess many of the characteristics of MLV retroviral vectors, 
and as mentioned present the additional advantages of being able to transduce quiescent 
cells. The diversity of human gene therapy as well as the possibility of patients being treated 
more than once with viral vectors, which are recognized by the adaptive immune system, 
leaves space to both alternative vector technologies. MLV present a large safety record in 
clinical application that cannot be discarded. Since MLV retroviral vectors are not derived 
from human viruses they also show reduced vector genome mobilization and recombination 
in the host-cell and pre-existing immune response against the retroviral vector particle. 
Additionally, they are simple to develop in terms of plasmid cloning, transfection and cell 
culture; and from the clinical perspective they can be easily produced at large scale from 
stable packaging cell lines with satisfactory yields. From the manufacturing point of view, 
HIV-1 derived vector still requires further optimization, particularly in what concerns cell 
line development. There is still less clinical experience with this vector and the results on the 
ongoing clinical trials will be certainly important for their improvement. 
Thus the recent manufacturing strategies together with future innovations will certainly be 
important to increase productivity, stability, quality and safety of retroviral and lentiviral 
vectors for clinical applications. 
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